Drugs / MN rgp160
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00001037 | ? → May 1995 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MN rgp160 | “200 mcg MN rgp160 vaccine (Immuno-AG)” NCT00001037 ↗ |
| Known as | Immuno-AG | “200 mcg MN rgp160 vaccine (Immuno-AG)” NCT00001037 ↗ |
| Modality | Vaccine | “200 mcg MN rgp160 vaccine (Immuno-AG)” NCT00001037 ↗ |